

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3833002/publications.pdf>

Version: 2024-02-01

261
papers

7,631
citations

57758

44
h-index

79698

73
g-index

273
all docs

273
docs citations

273
times ranked

7916
citing authors

#	ARTICLE	IF	CITATIONS
1	Segregation analysis and variance components analysis of bone mineral density in healthy families. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 2017-2022.	2.8	293
2	The UDP Glucuronosyltransferase Gene Super family: Suggested Nomenclature Based on Evolutionary Divergence. <i>DNA and Cell Biology</i> , 1991, 10, 487-494.	1.9	267
3	UDP-glucuronosyltransferase activities. <i>Biochemical Pharmacology</i> , 1983, 32, 953-955.	4.4	208
4	A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk. <i>Genome Research</i> , 1999, 9, 936-949.	5.5	193
5	Wine, Beer, and Mortality in Middle-aged Men From Eastern France. <i>Archives of Internal Medicine</i> , 1999, 159, 1865.	3.8	176
6	Drug metabolizing enzymes in the brain and cerebral microvessels. <i>Brain Research Reviews</i> , 1991, 16, 65-82.	9.0	175
7	Intima-media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort. <i>Journal of Hypertension</i> , 1998, 16, 1593-1602.	0.5	170
8	Increased protein glycation in cerebrospinal fluid of Alzheimer's disease 2 2Abbreviations: AD, Alzheimer's disease; AGEs, advanced glycation end products; apo, apolipoprotein; BSA, bovine serum albumin; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate buffer saline.. <i>Neurobiology of Aging</i> , 2001, 22, 397-402.	3.1	148
9	IL-6, TNF- α and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. <i>Atherosclerosis</i> , 2003, 170, 277-283.	0.8	137
10	Determination of Serum Cystatin C: Biological Variation and Reference Values. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 850-7.	2.3	131
11	Objectives, Design and Recruitment of a Familial and Longitudinal Cohort for Studying Gene-Environment Interactions in the Field of Cardiovascular Risk: The Stanislas Cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 35-42.	2.3	130
12	Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. <i>Biochemical Pharmacology</i> , 1993, 45, 647-658.	4.4	105
13	Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. <i>FEBS Letters</i> , 1998, 425, 225-228.	2.8	97
14	A new aspect of the protective functions of the blood-brain barrier: Activities of four drug-metabolizing enzymes in isolated rat brain microvessels. <i>Life Sciences</i> , 1988, 42, 2515-2523.	4.3	95
15	Genetic determinants of blood pressure regulation. <i>Journal of Hypertension</i> , 2005, 23, 2127-2143.	0.5	94
16	Plasma lecithin:cholesterol acyltransferase " reference values and effects of xenobiotics. <i>Clinica Chimica Acta</i> , 1983, 133, 85-96.	1.1	88
17	The theory of reference values: an unfinished symphony. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 47-64.	2.3	88
18	Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. <i>European Journal of Human Genetics</i> , 2001, 9, 780-786.	2.8	86

#	ARTICLE	IF	CITATIONS
19	Blood Activity of Cu/Zn Superoxide Dismutase, Glutathione Peroxidase and Catalase in Alzheimerâ€™s Disease: A Case-Control Study. <i>Gerontology</i> , 1990, 36, 306-313.	2.8	84
20	Rapid spectrophotometric method for serum glutathione S-transferases activity. <i>Clinica Chimica Acta</i> , 2002, 326, 131-142.	1.1	81
21	Transcription Factor and Drug-Metabolizing Enzyme Gene Expression in Lymphocytes from Healthy Human Subjects. <i>Drug Metabolism and Disposition</i> , 2008, 36, 182-189.	3.3	80
22	Growing Significance of Myeloperoxidase in Non-infectious Diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 2-8.	2.3	78
23	Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. <i>Free Radical Biology and Medicine</i> , 2000, 28, 129-140.	2.9	75
24	The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. <i>European Journal of Human Genetics</i> , 2002, 10, 841-850.	2.8	75
25	High Sensitivity C-Reactive Protein: Biological Variations and Reference Limits. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1003-1011.	2.3	74
26	Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders. , 2014, 144, 134-161.		74
27	An Isocratic Liquid Chromatographic Method with Diode-Array Detection for the Simultaneous Determination of Î±-Tocopherol, Retinol, and Five Carotenoids in Human Serum. <i>Journal of Chromatographic Science</i> , 2002, 40, 69-76.	1.4	73
28	Identification of <i>cis</i>- and <i>trans</i>-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels. <i>Circulation Research</i> , 2011, 109, 554-563.	4.5	72
29	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 721-730.	2.3	70
30	Biological variations, genetic polymorphisms and familial resemblance of TNF-Î± and IL-6 concentrations: STANISLAS cohort. <i>European Journal of Human Genetics</i> , 2005, 13, 109-117.	2.8	70
31	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. <i>Biochemical Pharmacology</i> , 1985, 34, 2235-2249.	4.4	69
32	The glucuronosyltransferases: What progress can pharmacologists expect from molecular biology and cellular enzymology?. <i>Biochemical Pharmacology</i> , 1987, 36, 983-989.	4.4	67
33	Î³-Glutamyltransferase: Nucleotide sequence of the human pancreatic cDNA. <i>Biochemical Pharmacology</i> , 1992, 43, 2527-2533.	4.4	65
34	Stereochemical heterogeneity of hepatic UDP-glucuronosyltransferase activity in rat liver microsomes. <i>Biochemical Pharmacology</i> , 1981, 30, 1457-1461.	4.4	61
35	Dairy product consumption, calcium intakes, and metabolic syndromeâ€™-related factors over 5 years in the STANISLAS study. <i>Nutrition</i> , 2013, 29, 519-524.	2.4	60
36	Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 841-852.	2.3	58

#	ARTICLE	IF	CITATIONS
37	Distribution of cytochrome p450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. <i>Biochemical Pharmacology</i> , 1990, 40, 2145-2151.	4.4	57
38	An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. <i>Human Genetics</i> , 1990, 84, 373-5.	3.8	52
39	Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. <i>Atherosclerosis</i> , 1998, 140, 89-95.	0.8	51
40	High Prevalence of Metabolic Syndrome in Iran in Comparison with France: What Are the Components That Explain This?. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 181-188.	1.3	51
41	Lipid Free Apolipoprotein E Binds to the Class B Type I Scavenger Receptor I (SR-BI) and Enhances Cholesteryl Ester Uptake from Lipoproteins. <i>Journal of Biological Chemistry</i> , 2002, 277, 36092-36099.	3.4	50
42	The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 733-47.	2.3	50
43	Simultaneous measurement of reactive oxygen species and reduced glutathione using capillary electrophoresis and laser-induced fluorescence detection in cultured cell lines. <i>Electrophoresis</i> , 1999, 20, 2938-2944.	2.4	48
44	Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. <i>Cell Biology and Toxicology</i> , 1989, 5, 1-14.	5.3	45
45	A Multilocus Genotyping Assay for Cardiovascular Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 561-6.	2.3	45
46	Brain mitochondrial cytochrome P-450 _{osc} : Spectral and catalytic properties. <i>Archives of Biochemistry and Biophysics</i> , 1987, 254, 592-596.	3.0	44
47	Characterization of distinct forms of cytochromes P-450, epoxide metabolizing enzymes and UDP-glucuronosyltransferases in rat skin. <i>Biochemical Pharmacology</i> , 1989, 38, 2187-2194.	4.4	42
48	Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. <i>Atherosclerosis</i> , 2003, 167, 223-230.	0.8	42
49	Ethoxyresorufin O-deethylase activity in rat brain subcellular fractions. <i>Neuroscience Letters</i> , 1987, 76, 58-62.	2.1	40
50	Phenobarbital inducible UDP-glucuronosyltransferase is responsible for glucuronidation of 3-azido-2-deoxythymidine: Characterization of the enzyme in human and rat liver microsomes. <i>Archives of Biochemistry and Biophysics</i> , 1990, 281, 264-270.	3.0	40
51	Differential effects of human recombinant interleukin-1 ^β and dexamethasone on hepatic drug-metabolizing enzymes in male and female rats. <i>Biochemical Pharmacology</i> , 1993, 45, 2269-2277.	4.4	40
52	Extension of variance components approach to incorporate temporal trends and longitudinal pedigree data analysis. <i>Genetic Epidemiology</i> , 2002, 22, 221-232.	1.3	40
53	Enzymes and pharmacogenetics of cardiovascular drugs. <i>Clinica Chimica Acta</i> , 2007, 381, 26-31.	1.1	40
54	Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 411-418.	1.9	40

#	ARTICLE	IF	CITATIONS
55	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: Comparison between human and mammalian species activities. <i>Chemico-Biological Interactions</i> , 1984, 52, 173-184.	4.0	38
56	Compared Effect of Immunosuppressive Drugs Cyclosporine A and Rapamycin on Cholesterol Homeostasis Key Enzymes CYP27A1 and HMG-CoA Reductase. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 100, 392-397.	2.5	37
57	Rapid liquid chromatographic assay of glutathione in cultured cells. <i>Biomedical Chromatography</i> , 1993, 7, 86-89.	1.7	36
58	Evidence for the pro-oxidant effect of $\hat{1}^3$ -glutamyltranspeptidaseâ€“related enzyme11H. Aberkane and J. F. Salazar contributed equally to this work.. <i>Free Radical Biology and Medicine</i> , 2000, 29, 825-833.	2.9	35
59	Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. <i>Neuroscience Letters</i> , 2003, 349, 95-98.	2.1	35
60	Modulation of UDPGlucuronosyltransferase Activity in Rats by Dietary Lipids. <i>Journal of Nutrition</i> , 1986, 116, 2034-2043.	2.9	34
61	In Vivo Study of the Elimination from Rat Brain of an Intracerebrally Formed Xenobiotic Metabolite, 1-Naphthyl- $\hat{2}$ -D-Glucuronide. <i>Journal of Neurochemistry</i> , 1991, 56, 1163-1168.	3.9	34
62	Interaction between human amphipathic apolipoproteins and amyloid $\hat{1}^2$ -peptide: surface plasmon resonance studies. <i>FEBS Letters</i> , 1996, 383, 9-12.	2.8	34
63	Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1999, 1454, 296-308.	3.8	34
64	A Genome-Wide Association Study Identifies rs2000999 as a Strong Genetic Determinant of Circulating Haptoglobin Levels. <i>PLoS ONE</i> , 2012, 7, e32327.	2.5	34
65	Differential toxicity of aflatoxin B1 in male and female rats: Relationship with hepatic drug-metabolizing enzymes. <i>Biochemical Pharmacology</i> , 1982, 31, 3057-3062.	4.4	33
66	ELISA of 6-beta-hydroxycortisol in human urine: Diurnal variations and effects of antiepileptic therapy. <i>Clinica Chimica Acta</i> , 1986, 157, 267-276.	1.1	33
67	Glucuronidation in the caco-2 human intestinal cell line: Induction of UDP-glucuronosyltransferase $\hat{1}^{\wedge}6$. <i>Biochemical Pharmacology</i> , 1995, 50, 557-561.	4.4	33
68	Serum Total Antioxidant Status, Erythrocyte Superoxide Dismutase and Whole-Blood Glutathione Peroxidase Activities in the Stanislas Cohort: Influencing Factors and Reference Intervals. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 209-15.	2.3	33
69	Reconstituted Epidermis: A Novel Model for the Study of Drug Metabolism in Human Epidermis. <i>Journal of Investigative Dermatology</i> , 1990, 94, 749-752.	0.7	32
70	Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. <i>European Journal of Pharmacology</i> , 2005, 527, 1-22.	3.5	32
71	A Prospective Study on the Prevalence of Metabolic Syndrome Among Healthy French Families: Two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor- \hat{A}) are revealed in the offspring of parents with metabolic syndrome. <i>Diabetes Care</i> , 2005, 28, 675-682.	8.6	32
72	$\hat{1}^3$ -Glutamyltranspeptidase-Dependent Metabolism of 4-Hydroxynonenalâ€“Glutathione Conjugate. <i>Archives of Biochemistry and Biophysics</i> , 2002, 397, 18-27.	3.0	31

#	ARTICLE	IF	CITATIONS
73	Enzyme mediated superoxide radical formation initiated by exogenous molecules in rat brain preparations. <i>Toxicology and Applied Pharmacology</i> , 1991, 110, 107-117.	2.8	29
74	Enzyme induction by drugs and toxins. <i>Clinica Chimica Acta</i> , 1992, 209, 109-121.	1.1	29
75	Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. , 1996, 13, 179-192.		29
76	The Lipoprotein Lipase Serine 447 Stop Polymorphism Is Associated With Altered Serum Carotenoid Concentrations in the Stanislas Family Study. <i>Journal of the American College of Nutrition</i> , 2007, 26, 655-662.	1.8	29
77	DNA polymorphisms of human apolipoprotein Aâ€”IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population. <i>Clinical Genetics</i> , 1994, 46, 248-254.	2.0	29
78	Î³-Glytamytransferase of rabbit liver: Kinetic study of phenobarbital induction and in vitro solubilization by bile salts. <i>Toxicology and Applied Pharmacology</i> , 1980, 55, 1-7.	2.8	28
79	Allele frequency distribution of the (TG)n(AG)m microsatellite in the apolipoprotein C-II gene. <i>Genomics</i> , 1992, 12, 63-68.	2.9	28
80	Apolipoprotein E Activates Akt Pathway in Neuro-2a in an Isoform-Specific Manner. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 83-87.	2.1	28
81	Synthesis and in Vitro Antioxidant Activity of Glycyrrhetic Acid Derivatives Tested with the Cytochrome P450/NADPH System. <i>Chemical and Pharmaceutical Bulletin</i> , 2004, 52, 1436-1439.	1.3	28
82	A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. <i>Journal of Lipid Research</i> , 2013, 54, 535-541.	4.2	28
83	Expression and regulation of drug metabolizing enzymes in an immortalized rat hepatocyte cell line. <i>Biochemical Pharmacology</i> , 1991, 42, 1345-1351.	4.4	27
84	Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. <i>Journal of Lipid Research</i> , 2003, 44, 430-436.	4.2	27
85	Genetic and environmental contributions to serum retinol and Î±-tocopherol concentrations: the Stanislas Family Study. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 1034-1044.	4.7	27
86	Comparative study of clofibrac acid and bilirubin glucuronidation in human liver microsomes. <i>Biochemical Pharmacology</i> , 1987, 36, 3923-3927.	4.4	26
87	The structure of human apolipoprotein E2, E3 and E4 in solution. 2. Multidomain organization correlates with the stability of apoE structure. <i>Biophysical Chemistry</i> , 2006, 119, 170-185.	2.8	26
88	Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents. <i>Xenobiotica</i> , 1987, 17, 445-457.	1.1	25
89	Novel inhibitors and substrates of bilirubin: UDP-glucuronosyltransferase Arylalkylcarboxylic acids. <i>FEBS Journal</i> , 1989, 183, 653-659.	0.2	25
90	Biological Effects of Eleven Combined Oral Contraceptives on Serum Triglycerides, Î³-Glutamytransferase, Alkaline Phosphatase, Bilirubin and other Biochemical Variables. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 871-8.	2.3	25

#	ARTICLE	IF	CITATIONS
91	Kinetics of apolipoprotein E isoforms-binding to the major glycosaminoglycans of the extracellular matrix. <i>FEBS Letters</i> , 1999, 459, 353-357.	2.8	25
92	Effects of pro-inflammatory cytokines on apolipoprotein E secretion by a human astrocytoma cell line (CCF-STTG1). , 2000, 18, 9-16.		25
93	PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 535-40.	2.3	25
94	Effect of Chronic Ethanol Administration on Gamma-Glutamyltransferase Activities in Plasma and in Hepatic Plasma Membranes of Male and Female Rats. <i>Enzyme</i> , 1982, 28, 251-257.	0.7	24
95	Effect of 1-benzylimidazole on cytochromes P-450 induction and on the activities of epoxide hydrolases and UDP-glucuronosyltransferases in rat liver. <i>Biochemical Pharmacology</i> , 1988, 37, 3297-3304.	4.4	24
96	Dextromethorphan O-demethylase activity in rat brain microsomes. <i>Neuroscience Letters</i> , 1995, 187, 65-68.	2.1	24
97	Lipoprotein lipase (C/G)447 polymorphism and blood pressure in the Stanislas Cohort. <i>Journal of Hypertension</i> , 2000, 18, 1775-1781.	0.5	24
98	Sexâ€dependent Associations of Leptin With Metabolic Syndromeâ€related Variables: The Stanislas Study. <i>Obesity</i> , 2010, 18, 196-201.	3.0	24
99	Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. <i>Drug Metabolism Reviews</i> , 2014, 46, 33-56.	3.6	24
100	Glucuronidation of 3â€azido-3â€deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1992, 1139, 20-24.	3.8	23
101	Induction and immunological characterization of the uridine diphosphate-glucuronosyltransferase conjugating 1-naphthol in the rat choroid plexus. <i>Neuroscience Letters</i> , 1994, 175, 37-40.	2.1	23
102	Differential Role of CYP2E1 Binders and Isoniazid on CYP2E1 Protein Modification in NADPH-dependent Microsomal Oxidative Reactions: Free Radical Scavenging Ability of Isoniazid. <i>Free Radical Research</i> , 2002, 36, 893-903.	3.3	23
103	Effect of HMGCoA Reductase Inhibitors on Cytochrome P450 Expression in Endothelial Cell Line. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 49, 306-315.	1.9	23
104	Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. <i>Clinica Chimica Acta</i> , 2009, 403, 198-202.	1.1	23
105	Expression of inflammatory molecules and associations with BMI in children. <i>European Journal of Clinical Investigation</i> , 2010, 40, 388-392.	3.4	23
106	Differential action of thyroid hormones and chemically related compounds on the activity of UDP-glucuronosyltransferases and cytochrome P-450 isozymes in rat liver. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1990, 1035, 12-19.	2.4	22
107	Family study of the relationship between height and cardiovascular risk factors in the STANISLAS cohort. <i>International Journal of Epidemiology</i> , 2003, 32, 607-614.	1.9	22
108	Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2002, 1583, 99-107.	2.4	21

#	ARTICLE	IF	CITATIONS
109	Interaction between CYP1A1 T3801C and AHR G1661A polymorphisms according to smoking status on blood pressure in the Stanislas cohort. <i>Journal of Hypertension</i> , 2006, 24, 2199-2205.	0.5	21
110	Alcohol Consumption, Beverage Preference, and Diet in Middle-Aged Men from the STANISLAS Study. <i>Journal of Nutrition and Metabolism</i> , 2012, 2012, 1-6.	1.8	21
111	Repression of cytochrome P450 by cytokines: IL-1 β counteracts clofibrac acid induction of CYP4A in cultured fetal rat hepatocytes. <i>Cell Biology and Toxicology</i> , 1993, 9, 307-313.	5.3	20
112	Heparin specifically inhibits binding of apolipoprotein E to amyloid β -peptide. <i>Neuroscience Letters</i> , 2000, 280, 131-134.	2.1	20
113	Visfatin: The Link Between Inflammation and Childhood Obesity. <i>Diabetes Care</i> , 2009, 32, e71-e71.	8.6	20
114	Characterization and quantification of serum lipoprotein subfractions by capillary isotachopheresis: relationships with lipid, apolipoprotein, and lipoprotein levels. <i>Journal of Lipid Research</i> , 1999, 40, 2125-2133.	4.2	20
115	Measurement of plasma gamma-glutamyltransferase in clinical chemistry: kinetic basis and standardisation propositions. <i>Clinica Chimica Acta</i> , 1981, 112, 187-195.	1.1	19
116	gamma-glutamyltransferase from human hepatoma cell lines: Purification and cell culture of HepG2 on microcarriers. <i>Clinica Chimica Acta</i> , 1990, 191, 221-232.	1.1	19
117	Malondialdehyde adducts to, and fragmentation of, apolipoprotein B from human plasma. <i>Clinica Chimica Acta</i> , 1993, 218, 39-46.	1.1	19
118	Bivariate familial correlation analysis of quantitative traits by use of estimating equations: Application to a familial analysis of the insulin resistance syndrome. , 1999, 16, 69-83.		19
119	Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2000, 1484, 14-28.	2.4	19
120	Expression of rat renal gamma γ glutamyltransferase cDNA in Escherichia coli. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 1040-1046.	2.1	18
121	The 5' untranslated region of the human β -glutamyl transferase mRNA contains a tissue-specific active translational enhancer. <i>FEBS Letters</i> , 1993, 332, 88-92.	2.8	18
122	Low and very low density lipoprotein composition and resistance to copper-induced oxidation are not notably modified in smokers. <i>Clinica Chimica Acta</i> , 1997, 265, 1-12.	1.1	18
123	Soluble Transferrin Receptor (sTfR): Biological Variations and Reference Limits. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 1162-8.	2.3	18
124	Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 981-8.	2.3	18
125	Age-related variations of enzymatic defenses against free radicals and peroxides. , 1992, 62, 359-367.		18
126	Covalent attachment of epoxide hydrolase to dextran. <i>Enzyme and Microbial Technology</i> , 1985, 7, 66-72.	3.2	17

#	ARTICLE	IF	CITATIONS
127	Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. <i>Neuroscience Letters</i> , 1998, 242, 117-119.	2.1	17
128	The structure of human apolipoprotein E2, E3 and E4 in solution. <i>Biophysical Chemistry</i> , 2006, 119, 158-169.	2.8	17
129	Phenobarbital Induction of Cytochrome P-450 and UDPGlucuronosyltransferase in Rabbit Liver Plasma Membranes. <i>Enzyme</i> , 1982, 28, 41-47.	0.7	16
130	Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. <i>Pharmacological Research Communications</i> , 1984, 16, 227-241.	0.2	16
131	Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds. <i>General Pharmacology</i> , 1989, 20, 407-412.	0.7	16
132	Study of reference values and biological variation: a necessity and a model for Preventive Medicine Centers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 810-6.	2.3	16
133	Familial Studies on the Genetics of Cardiovascular Diseases: the Stanislas Cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 827-32.	2.3	15
134	Clinical necessity of partitioning of human plasma haptoglobin reference intervals by recently-discovered rs2000999. <i>Clinica Chimica Acta</i> , 2012, 413, 1618-1624.	1.1	15
135	Protein and enzyme release from human leukocytes: Influence of phenothiazine derivatives. <i>Chemico-Biological Interactions</i> , 1977, 19, 173-183.	4.0	14
136	Certification of an enzyme reference material for alkaline phosphatase (CRM 371). <i>Clinical Biochemistry</i> , 1991, 24, 159-168.	1.9	14
137	Candidate Gene Polymorphism in Cardiovascular Disease: A Comparative Study of Frequencies between a French and an Italian Population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 146-54.	2.3	14
138	Family Studies: Their Role in the Evaluation of Genetic Cardiovascular Risk Factors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 1085-96.	2.3	14
139	Effect of six candidate genes on early aging in a French population. <i>Aging Clinical and Experimental Research</i> , 2003, 15, 111-116.	2.9	14
140	Pharmacogenomics of Drugs Affecting the Cardiovascular System. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 590-9.	2.3	14
141	Metabolic syndrome-related composite factors over 5years in the STANISLAS Family Study: Genetic heritability and common environmental influences. <i>Clinica Chimica Acta</i> , 2010, 411, 833-839.	1.1	14
142	Immobilization of pig liver microsomes. <i>Applied Biochemistry and Biotechnology</i> , 1986, 12, 199-213.	2.9	13
143	Monoclonal antibodies to human kidney gamma-glutamyltransferase. <i>Clinica Chimica Acta</i> , 1988, 174, 149-161.	1.1	13
144	Effect of hypolipidemic compounds on lauric acid hydroxylation and phase II enzymes. <i>Biochemical Pharmacology</i> , 1989, 38, 1963-1969.	4.4	13

#	ARTICLE	IF	CITATIONS
145	Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. <i>Atherosclerosis</i> , 2007, 191, 369-376.	0.8	13
146	Epistatic study reveals two genetic interactions in blood pressure regulation. <i>BMC Medical Genetics</i> , 2013, 14, 2.	2.1	13
147	Multiple forms of serum aminopeptidases separated by micro two-dimensional electrophoresis under non-denaturing conditions. <i>Electrophoresis</i> , 1986, 7, 471-475.	2.4	12
148	Molecular and functional characterization of recombinant human gamma-glutamyltransferase. Coupling of its activity to glutathione levels in V79 cells. <i>FEBS Journal</i> , 1994, 222, 1009-1016.	0.2	12
149	Single-Step Purification of Two Functional Human Apolipoprotein E Variants Hyperexpressed in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 1996, 7, 407-414.	1.3	12
150	High Sensitivity C-Reactive Protein (CRP) Reference Intervals in the Elderly. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 1169-70.	2.3	12
151	Age- and sex-related reference values for serum insulin concentration and its biological determinants in a French healthy population. The STANISLAS cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 1140-9.	2.3	12
152	Polymorphism of the 5-HT2A receptor gene and food intakes in children and adolescents: the Stanislas Family Study. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 467-470.	4.7	12
153	Hepatic membrane gamma-glutamyltransferase solubilization facilitated after administration of phenobarbital. <i>Pharmacological Research Communications</i> , 1979, 11, 211-220.	0.2	11
154	Automated quantification of bone and liver alkaline phosphatase isoenzymes of human serum. <i>Clinica Chimica Acta</i> , 1980, 107, 203-210.	1.1	11
155	UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species. <i>Biochemical Pharmacology</i> , 1981, 30, 2507-2510.	4.4	11
156	Structural changes of liver microsomes in rat during neonatal life: Influence on the glucuronidation rates of various substrates. <i>Biochemical and Biophysical Research Communications</i> , 1984, 119, 29-34.	2.1	11
157	Stereospecific induction of rat liver bilirubin UDPglucuronosyltransferase and lauric acid 12-hydroxylation by the isomers of 2-phenylpropionic acid. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1986, 882, 469-472.	2.4	11
158	Identification of gamma-glutamyltransferase in rat liver plasma membranes after two-dimensional electrophoresis. <i>Electrophoresis</i> , 1986, 7, 83-88.	2.4	11
159	Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells. <i>General Pharmacology</i> , 1991, 22, 677-684.	0.7	11
160	Sources of variability of human plasma apolipoprotein A-IV levels and relationships with lipid metabolism. <i>Genetic Epidemiology</i> , 1994, 11, 101-114.	1.3	11
161	Expression of the human UDP-glucuronosyltransferase UGT116 in <i>Escherichia coli</i> . <i>FEBS Letters</i> , 1994, 339, 195-199.	2.8	11
162	Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. <i>Biochemical Journal</i> , 1999, 338, 281.	3.7	11

#	ARTICLE	IF	CITATIONS
163	Associations of Apolipoprotein E Concentration and Polymorphism with Lipids and Apolipoprotein Levels in Chinese from Beijing and Shanghai. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 655-9.	2.3	11
164	Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2000, 1484, 29-40.	2.4	11
165	Control of apolipoprotein E secretion in the human hepatoma cell line KYN-2. <i>Cell Biochemistry and Function</i> , 2001, 19, 51-58.	2.9	11
166	Proteinâ€œlipid interactions in reconstituted high density lipoproteins: apolipoprotein and cholesterol influence. <i>Chemistry and Physics of Lipids</i> , 2001, 113, 67-82.	3.2	11
167	The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype. <i>Biological Chemistry</i> , 2005, 386, 441-52.	2.5	11
168	Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1339-46.	2.3	11
169	Clinical significance of a new isoform of serum alanine aminopeptidase; relationship with liver disease and alcohol consumption. <i>Clinica Chimica Acta</i> , 1989, 179, 23-31.	1.1	10
170	Oral contraceptives stimulate the excretion of clofibrac acid glucuronide in women and female rats. <i>General Pharmacology</i> , 1991, 22, 393-397.	0.7	10
171	Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. <i>Clinica Chimica Acta</i> , 1996, 253, 127-143.	1.1	10
172	An intronic promoter controls the expression of truncated human \hat{I}^3 -glutamyltransferase mRNAs1. <i>FEBS Letters</i> , 1998, 434, 51-56.	2.8	10
173	Association of Apolipoprotein E Polymorphism and Concentration with Serum Lipids and Apo-lipoprotein Level in the Chinese from Shanghai. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 615-619.	2.3	10
174	Charge-based heterogeneity of human plasma lipoproteins at hypertriglyceridemia: capillary isotachopheresis study. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 530-543.	2.8	10
175	CYTOCHROME P-450-MEDIATED DIFFERENTIAL OXIDATIVE MODIFICATION OF PROTEINS: ALBUMIN, APOLIPOPROTEIN E, AND CYP2E1 AS TARGETS. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2004, 67, 2061-2071.	2.3	10
176	Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics and <i>in vitro</i> diagnostics to generate reliable results. <i>Proteomics - Clinical Applications</i> , 2007, 1, 1016-1035.	1.6	10
177	Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: Review and hypothesis. <i>Vascular Pharmacology</i> , 2008, 48, 70-75.	2.1	10
178	Gamma-glutamyltransferase activity of liver plasma membranes in phenobarbital â€” Treated rabbits. <i>Pharmacological Research Communications</i> , 1981, 13, 909-919.	0.2	9
179	Some kinetic properties of \hat{I}^3 -glutamyltransferase from rabbi liver. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1981, 658, 220-231.	2.6	9
180	Peroxisome proliferators as inducers and substrates of UDP-glucuronosyltransferases. <i>Biology of the Cell</i> , 1993, 77, 13-16.	2.0	9

#	ARTICLE	IF	CITATIONS
181	Heterogeneity of hepatic UDP-Glucuronosyltransferase activities: Investigations of isoenzymes involved in p-nitrophenol glucuronidation. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1993, 106, 241-248.	0.5	9
182	Reference Limits of Apolipoprotein A-I and Apolipoprotein B Using an IFCC Standardized Immunonephelometric Method. <i>Clinical Chemistry and Laboratory Medicine</i> , 1995, 33, 337-42.	2.3	9
183	Gamma-glutamyltransferase expression during all-transretinoic acid-induced differentiation of hematopoietic cell lines. <i>FEBS Letters</i> , 1995, 369, 183-186.	2.8	9
184	Homo- and hetero-complexes of exchangeable apolipoproteins in solution and in lipid-bound form. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2003, 59, 1127-1137.	3.9	9
185	Personalized therapy and pharmacogenomics: future perspective. <i>Pharmacogenomics</i> , 2009, 10, 927-930.	1.3	9
186	Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 121-128.	0.6	9
187	Influence of three inducers on rabbit gamma-glutamyltransferase. <i>Pharmacological Research Communications</i> , 1980, 12, 557-565.	0.2	8
188	Evaluation of a versatile reversed-phase high-performance liquid chromatographic system using cethexonium bromide as ion-pairing reagent for the analysis of glucuronic acid conjugates. <i>Biomedical Applications</i> , 1989, 493, 137-147.	1.7	8
189	Genetic influences on blood pressure within the Stanislas Cohort. <i>Journal of Hypertension</i> , 2004, 22, 297-304.	0.5	8
190	Human formyl peptide receptor 1 (<i>FPR1</i>) c.32C>T SNP is associated with decreased soluble E-selectin levels. <i>Pharmacogenomics</i> , 2009, 10, 951-959.	1.3	8
191	Cellular and Molecular Aspects of Udp-Glucuronosyltransferases. <i>Drug Metabolism Reviews</i> , 1989, 20, 721-731.	3.6	7
192	Length and sequence variation in the apolipoprotein B intron 20 Alu repeat. <i>Genomics</i> , 1992, 14, 449-454.	2.9	7
193	Capillary electrophoretic analysis of recombinant human apolipoprotein E. <i>Journal of Chromatography A</i> , 1999, 853, 237-241.	3.7	7
194	Changes in Serum Apolipoprotein and Lipoprotein Profile After Alcohol Withdrawal: Effect of Apolipoprotein E Polymorphism. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 501-508.	2.4	7
195	Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors. <i>British Journal of Haematology</i> , 2004, 126, 392-397.	2.5	7
196	CCLM: Evolving to meet the needs of today's laboratory professionals and scientists. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 883-4.	2.3	7
197	Adipokine expression in adipose tissue and in peripheral blood mononuclear cells in children. <i>Clinica Chimica Acta</i> , 2009, 410, 85-89.	1.1	7
198	Systems medicine, stratified medicine, personalized medicine but not precision medicine. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 1-2.	0.3	7

#	ARTICLE	IF	CITATIONS
199	In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters. <i>European Journal of Medicinal Chemistry</i> , 1987, 22, 393-402.	5.5	6
200	Cloning and expression of a novel type (III) of human $\hat{1}^3$ -glutamyltransferase truncated mRNA. <i>FEBS Letters</i> , 1996, 394, 258-262.	2.8	6
201	Effect of Short- and Long-Term Storage on Human Serum and Recombinant Apolipoprotein E Concentration. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 525-8.	2.3	6
202	Effect of apolipoprotein E on cell viability in a human neuroblastoma cell line: influence of oxidation and lipid-association. <i>Neuroscience Letters</i> , 2000, 285, 173-176.	2.1	6
203	Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. <i>Vascular Pharmacology</i> , 2003, 40, 237-245.	2.1	6
204	Cardiovascular risk-associated allele frequencies for 15 genes in healthy elderly French and Chinese. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 817-22.	2.3	6
205	Pharmacy-based laboratory services: past or future and risk or opportunity?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 435-6.	2.3	6
206	Genetic profiling of human cell lines used as in vitro model to study cardiovascular pathophysiology and pharmacotoxicology. <i>Cell Biology and Toxicology</i> , 2009, 25, 561-571.	5.3	6
207	Kinetic constant determination of liver microsomal and purified UDP-glucuronosyltransferase after phenobarbital and 3-methylcholanthrene treatments in rats. <i>Comparative Biochemistry and Physiology Part C: Comparative Pharmacology</i> , 1986, 83, 127-131.	0.2	5
208	Localization of a regulatory region on the 5â€²-untranslated region of human hepatoma HepG2 $\hat{1}^3$ -glutamyltransferase mRNA and response to dexamethasone and antisense oligonucleotide treatment. <i>FEBS Letters</i> , 1994, 356, 307-310.	2.8	5
209	Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps. <i>Current Drug Metabolism</i> , 2009, 10, 410-419.	1.2	5
210	Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin. <i>Pharmacogenomics</i> , 2012, 13, 1215-1218.	1.3	5
211	Human Apolipoprotein E concentration in response to diseases and therapeutic treatments. <i>Drug Development Research</i> , 2002, 56, 95-110.	2.9	4
212	Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. <i>Personalized Medicine</i> , 2007, 4, 393-412.	1.5	4
213	Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy. <i>Pharmacogenomics</i> , 2011, 12, 681-691.	1.3	4
214	Clinical Chemistry and Laboratory Medicine: progress and new challenges for our 50-year-old journal. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 5-7.	2.3	4
215	Variations in sialic acid content of gamma-glutamyltransferase: a consequence for immunochemical determinations?. <i>Clinica Chimica Acta</i> , 1985, 148, 21-30.	1.1	3
216	$\hat{1}^3$ -Glutamyltransferase reference material: An example of International cooperation. <i>Clinica Chimica Acta</i> , 1988, 173, 19-26.	1.1	3

#	ARTICLE	IF	CITATIONS
217	Biochemical values of immigrant groups in north-east France. <i>Annals of Human Biology</i> , 1990, 17, 277-287.	1.0	3
218	An avidin-biotin ELISA for the measurement of mitochondrial aspartate aminotransferase in human serum. <i>Journal of Immunological Methods</i> , 1990, 128, 203-209.	1.4	3
219	Effects of RP 52028 and phenobarbital on mRNA levels of inducible and constitutive sex-specific cytochrome P450 isozymes in rat liver. <i>Biochemical Pharmacology</i> , 1991, 42, 1053-1060.	4.4	3
220	Heterogeneity of Hepatic Microsomal UDP-Glucuronosyltransferase(s) Activities: A New Kinetic Approach for the Study of Induction and Specificity. <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 591-596.	3.3	3
221	Glycosylation of gamma-glutamyltransferase is modified by ethanol in H5â€“6 hepatoma cell line. <i>Clinica Chimica Acta</i> , 1994, 225, 1-15.	1.1	3
222	Gene transfer technologies for the production of enzyme and protein reference materials. <i>Clinica Chimica Acta</i> , 1997, 257, 3-23.	1.1	3
223	From human genetic variations to prediction of risks and responses to drugs and the environment. <i>Personalized Medicine</i> , 2007, 4, 95-104.	1.5	3
224	Capillary isotachopheresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 2. ApoE and apoC-III relations in triglyceride clearance. <i>Molecular and Cellular Biochemistry</i> , 2009, 325, 25-40.	3.1	3
225	Capillary isotachopheresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins. <i>Molecular and Cellular Biochemistry</i> , 2009, 325, 41-51.	3.1	3
226	Functional genomics towards personalized healthcare. <i>Personalized Medicine</i> , 2009, 6, 19-32.	1.5	3
227	Biological and genetic factors associated with ABCB1 and pregnane-X-receptor expressions in peripheral blood mononuclear cells in the STANISLAS cohort. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 27-32.	0.3	3
228	Competitive inhibition of glucuronidation by p-hydroxyphenyl hydantoin. <i>Biochemical Pharmacology</i> , 1975, 24, 152-154.	4.4	2
229	Induction of UDP-glucuronosyltransferase isozymes in male and female rat liver microsomes by an isoquinoline derivative (52028 RP). <i>Biochemical Pharmacology</i> , 1989, 38, 3634-3638.	4.4	2
230	Establishment of a V79 transfected cell line highly producing recombinant human Î³-glutamyltransferase. <i>Toxicology</i> , 1993, 82, 151-167.	4.2	2
231	Serum Total Antioxidant Status Is Higher in Postmenopausal Women and after Estrogen Replacement Therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 850-2.	2.3	2
232	Genetic and environmental contributions to serum ascorbic acid concentrations: the Stanislas Family Study. <i>British Journal of Nutrition</i> , 2006, 96, 1013-1020.	2.3	2
233	Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. <i>International Journal of Cardiology</i> , 2013, 168, 3057-3058.	1.7	2
234	From DMDI â€œDrug Metabolism and Drug Interactionsâ€“to DMPT â€œDrug Metabolism and Personalized Therapyâ€“. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 1.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Changes in Serum Apolipoprotein and Lipoprotein Profile After Alcohol Withdrawal: Effect of Apolipoprotein E Polymorphism. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 501-508.	2.4	2
236	Pharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European) Tj ETQq0 0 0 rgBT /Overlock 10 Tf the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 24, 85-9.	0.7	2
237	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mamalian species. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1987, 87, 513-522.	0.2	1
238	Study of the sequence tagged site (STS) in the beginning of human apo A4 gene region. <i>Nucleic Acids Research</i> , 1990, 18, 5576-5576.	14.5	1
239	Natriuretic peptides and evidence-based quality specifications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 355-7.	2.3	1
240	Genetic profiling in healthy subjects from the Stanislas cohort based on 24 polymorphisms: effects on biological variables. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 64-72.	2.3	1
241	Increasing laboratory medicine activities in China: research and publications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1209.	2.3	1
242	Functional genomics towards personalized healthcare and systems medicine. <i>Personalized Medicine</i> , 2011, 8, 227-242.	1.5	1
243	Conference Scene: Pharmacogenomics: from cell to clinic (Part 2). <i>Pharmacogenomics</i> , 2014, 15, 739-744.	1.3	1
244	Production, cross reactivity, and epitope analysis of monoclonal antibodies against rat kidney gamma glutamyltransferase. <i>Cell Biology and Toxicology</i> , 1990, 6, 157-70.	5.3	0
245	Viral Immortalization and Phenotypic Characterization of a Rat Hepatocyte Cell Line. <i>Cellular Physiology and Biochemistry</i> , 1992, 2, 349-358.	1.6	0
246	Human Genomics: The Basis of the Medicine of Tomorrow. Recent Progress in Molecular Biology Technology. First IFCC-Roche Conference "Singapore, 15-18 March 1998. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, .	2.3	0
247	Second Santorini Conference "From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment" <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, .	2.3	0
248	HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. , 2006, , 63-89.		0
249	CCLM: Expanding the science worldwide. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, .	2.3	0
250	From human genetic variations to prediction of risks and responses to drugs and the environment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 277-8.	2.3	0
251	Meeting Report: From human genetic variations to prediction of risks and responses to drugs and the environment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, .	2.3	0
252	Pharmacogenomics and Cardiovascular Drugs. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 413-446.	0.2	0

#	ARTICLE	IF	CITATIONS
253	Systems biology and personalized prevention. <i>Personalized Medicine</i> , 2009, 6, 265-268.	1.5	0
254	Parental precocious influences on offspring cardiovascular risk markers: an exploratory study in the STANISLAS Cohort. <i>Personalized Medicine</i> , 2009, 6, 343-352.	1.5	0
255	Pharmacogenomics and drug interactions. A specific journal. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 1.	0.3	0
256	Maintain the goals of <i>Drug Metabolism and Drug Interactions</i> . <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 183-4.	0.3	0
257	<i>Drug Metabolism and Drug Interactions</i> and the European Society of Pharmacogenomics and Theranostics. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 61-61.	0.3	0
258	Pharmacogenomics: from cell to clinic. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 133.	0.3	0
259	CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 207-209.	0.3	0
260	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. <i>Pharmacogenomics</i> , 2015, 16, 459-469.	1.3	0
261	Differential Susceptibility of Human Apolipoprotein E Isoforms to Oxidation and Consequences on their Interaction with Phospholipids. <i>Advances in Behavioral Biology</i> , 1998, , 31-38.	0.2	0